Results 131 to 140 of about 527 (153)

Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor

Annals of Pharmacotherapy
Objective: To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT). Data Sources: A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May ...
Cameron Lanier
exaly   +4 more sources

Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation

Expert Opinion on Drug Metabolism and Toxicology
Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. Cefepime is relatively resistant to hydrolysis by AmpC, and enmetazobactam inhibits all Ambler Class A extended spectrum β-lactamases (ESBLs). Hence, the combination is resistant to hydrolysis by many ESBLs.
Christopher A Darlow, William Hope, Vineet Dubey   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis

JAMA - Journal of the American Medical Association, 2023
Chi-Kuei Hsu, Wen-Wen Tsai, Chih-Cheng Lai   +2 more
exaly   +2 more sources

Cefepime/Enmetazobactam: First Approval

Drugs
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed by Allecra Therapeutics and ADVANZ PHARMA for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria. In February 2024,
exaly   +3 more sources

In complicated UTI or pyelonephritis, cefepime–enmetazobactam increased success vs. piperacillin–tazobactam at 14 d

Annals of Internal Medicine, 2023
Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328:1304-14. 36194218.
openaire   +2 more sources

Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728

Journal of Molecular Modeling, 2022
Antibiotic-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Staphylococcus aureus, and Enterobacterales infections are serious global health problems, and class A β-lactamases are one mechanism that leads to antibiotic resistance.
openaire   +2 more sources

Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The Medical Letter on Drugs and Therapeutics
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms.
openaire   +2 more sources

Cefepime/Enmetazobactam for Complicated Urinary Tract Infections

JAMA, 2022
Sonali D, Advani, Kimberly, Claeys
openaire   +2 more sources

Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery

ACS Infectious Diseases
The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India.
openaire   +2 more sources